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Clinics and pathology 
Disease 
Treatment related acute non lymphoblastic leukemia. 
Phenotype/cell stem origin 
M4 ANLL. 
Etiology 
One case, a 13 yr old boy; occurred 9 yrs after 
treatment for neuroblastoma with antitopoisomerase II. 





2.2 kb mRNA. 
Protein 
76 kDa; enzyme of the de novo synthesis of guanine 
nucleotides: amidotransferase that catalyzes the 






13-15 kb mRNA. 
 
Protein 
431 kDa; contains two DNA binding motifs (a AT 
hook, and Zinc fingers), a DNA methyl transferase 
motif, a bromodomain; transcriptional regulatory 
factor; nuclear localisation. 




Fusion of MLL exon 7 to GMPS. 
References 
Hirst M, Haliday E, Nakamura J, Lou L. Human GMP 
synthetase. Protein purification, cloning, and functional 
expression of cDNA. J Biol Chem. 1994 Sep 
23;269(38):23830-7 
Nakamura J, Straub K, Wu J, Lou L. The glutamine hydrolysis 
function of human GMP synthetase. Identification of an 
essential active site cysteine. J Biol Chem. 1995 Oct 
6;270(40):23450-5 
Pegram LD, Megonigal MD, Lange BJ, Nowell PC, Rappaport 
EF, Felix CA. t(3;11)(q25;q23) fuses MLL with the GMPS 
(guanosine 5'-monophosphate synthetase) gene in treatment-
related acute myeloid leukemia (AML). Blood. 1999 ; 94 
(numero Suppl 1). 
This article should be referenced as such: 
Huret JL. t(3;11)(q25;q23). Atlas Genet Cytogenet Oncol 
Haematol. 2000; 4(1):41. 
